NasdaqGS:SRRKBiotechs
Scholar Rock Holding (SRRK) Is Up 7.1% After Apitegromab BLA Resubmission And Dual Supply Strategy - Has The Bull Case Changed?
Scholar Rock Holding recently resubmitted its biologics license application for apitegromab, now including two fill-finish facilities, and received a September 30, 2026 PDUFA date, setting a clearer regulatory timetable for its lead spinal muscular atrophy therapy.
By securing two potential manufacturing routes for launch supply, the company has added redundancy to its production setup, which may reduce operational risk around eventual commercialization.
Next, we’ll examine how the updated...